236 related articles for article (PubMed ID: 33593880)
1. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
2. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
3. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
4. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
5. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
[TBL] [Abstract][Full Text] [Related]
8. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract][Full Text] [Related]
10. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer.
Papakyriacou I; Kutkaite G; Rúbies Bedós M; Nagarajan D; Alford LP; Menden MP; Mao Y
Nat Commun; 2024 Apr; 15(1):3581. PubMed ID: 38678024
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.
Bunch BL; Kodumudi KN; Scott E; Morse J; Weber AM; Berglund AE; Pilon-Thomas S; Markowitz J
Cancer Immunol Immunother; 2020 Dec; 69(12):2465-2476. PubMed ID: 32556443
[TBL] [Abstract][Full Text] [Related]
12. Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer.
Wang S; Zhang Y; Chen G; Zhao P; Wang X; Xu B; Yuan L
Int Immunopharmacol; 2024 May; 132():111988. PubMed ID: 38583239
[TBL] [Abstract][Full Text] [Related]
13. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.
Arranz-Nicolás J; Martin-Salgado M; Adán-Barrientos I; Liébana R; Del Carmen Moreno-Ortíz M; Leitner J; Steinberger P; Ávila-Flores A; Merida I
Cancer Immunol Immunother; 2021 Nov; 70(11):3277-3289. PubMed ID: 33837851
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E; Chen N; Nanda R
Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
[TBL] [Abstract][Full Text] [Related]
15. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
[TBL] [Abstract][Full Text] [Related]
16. Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure.
Saravanan R; Balasubramanian V; Sundaram S; Dev B; Vittalraj P; Pitani RS; Shanmugasundaram G; Rayala SK; Venkatraman G
J Cell Physiol; 2024 Apr; 239(4):e31203. PubMed ID: 38345361
[TBL] [Abstract][Full Text] [Related]
17. Circadian tumor infiltration and function of CD8
Wang C; Zeng Q; Gül ZM; Wang S; Pick R; Cheng P; Bill R; Wu Y; Naulaerts S; Barnoud C; Hsueh PC; Moller SH; Cenerenti M; Sun M; Su Z; Jemelin S; Petrenko V; Dibner C; Hugues S; Jandus C; Li Z; Michielin O; Ho PC; Garg AD; Simonetta F; Pittet MJ; Scheiermann C
Cell; 2024 May; 187(11):2690-2702.e17. PubMed ID: 38723627
[TBL] [Abstract][Full Text] [Related]
18. Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.
Mukhopadhyay A; Wright J; Shirley S; Canton DA; Burkart C; Connolly RJ; Campbell JS; Pierce RH
Gene Ther; 2019 Feb; 26(1-2):1-15. PubMed ID: 30323352
[TBL] [Abstract][Full Text] [Related]
19. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract][Full Text] [Related]
20. Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
Zhang S; Guo L; Zhang Z; Liu X; Chen W; Wei Y; Wang X; Wu Q
Cancer; 2024 Apr; 130(S8):1415-1423. PubMed ID: 38079306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]